CTLA4 (N-term) Rabbit Polyclonal Antibody AP52146PU-N from OriGene Technologies | Biocompare.com

Supplier Images

CTLA4 (N-term) Rabbit Polyclonal Antibody

Be the first to write a review!

Citations:

Supplier Page from
OriGene Technologies for
CTLA4 (N-term) Rabbit Polyclonal Antibody

The CTLA4 (N-term) Rabbit Polyclonal Antibody from OriGene Technologies is a Rabbit Polyclonal antibody. This antibody recognizes Human antigen. The CTLA4 (N-term) Rabbit Polyclonal Antibody has been validated for the following applications: Immunohistochemistry, and Western Blot.

Description

CTLA4 (N-term) rabbit polyclonal antibody, Aff - Purified

Product Specs
ItemCTLA4 (N-term) Rabbit Polyclonal Antibody
CompanyOriGene Technologies
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberAP52146PU-N
Quantity200 µl
ApplicationsIHC, WB
Concentrationlot specific
Conjugate/TagUnconjugated
PurityAffinity Chromatography on Protein A
ReactivityHuman
TargetCTLA4
IsotypeIg
HostRabbit
Antibody TypePrimary Antibodies
ImmunogenKLH conjugated synthetic peptide between 50-78 amino acids from the N-terminal region of Human CD152 / CTLA4
Domain/Region/TerminusN-term
Brand/TrademarkAcris Antibodies GmbH
NCBI Full Gene Namecytotoxic T-lymphocyte associated protein 4
NCBI Gene AliasesGRD4, CTLA-4, CELIAC3, CD, CD152, GSE, ALPS5, IDDM12
ClonalityPolyclonal
TypePrimary Antibodies
FormatPBS
State: Aff - Purified
State: Liquid purified Ig fraction
Preservative: 0.09% Sodium Azide

Add to Compare List

OriGene Technologies

OriGene Technologies

9620 Medical Center Drive # 200

Rockville, Maryland 20850

United States

Phone: 1-888-267-4436 (U.S. only) / 301-340-3188
301-340-9254

Company Profile

Website: http://www.origene.com

(1) The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervixPathology, research and practiceJanuary 1, 2020Karpathiou G, Chauleur C, Mobarki M, Peoc'h M.

(2) Expression of CD3, PD-L1 and CTLA-4 in mammary and extra-mammary Paget diseaseCancer immunology, immunotherapy : CIIAugust 1, 2018Karpathiou G, Chauleur C, Hathroubi S, Habougit C, Peoc'h M.

(3) Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristicsOncotargetMarch 21, 2017Karpathiou G, Casteillo F, Giroult JB, Forest F, Fournel P, Monaya A, Froudarakis M, Dumollard JM, Prades JM, Peoc'h M.

Be the First to Write a Review!